Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren, moxonidine, hydrochlorothiazide, and placebo crossover study in obesity-related hypertension
NL-OMON34799Phase 4Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren, moxonidine, hydrochlorothiazide and Placebo-COD Research Private Ltd in hypertension (HTN) (4 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Mean intrapersonal changes in endothelial function. Planned start Apr 2010; status: withdrawn.
02
Drugs
aliskirenmoxonidinehydrochlorothiazidePlacebo-COD Research Private Ltd
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NL-OMON34799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34799.